Ketorolac

Introduction Overview

Generic Name

ketorolac

Brand Name

Toradol

Dosage Form

oral tablets, intramuscular injection, intravenous injection, nasal spray

Drug Class

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Pharmacokinetics

Absorption:
Ketorolac exhibits rapid and nearly complete absorption when administered orally, with peak plasma concentrations typically achieved within 30 to 60 minutes after dosing. When given intramuscularly or intravenously, ketorolac reaches therapeutic plasma levels almost immediately, providing rapid onset of analgesic effect, which is crucial for managing moderate to severe pain. The bioavailability after oral administration is high, but absolute bioavailability is somewhat reduced due to first-pass hepatic metabolism. Factors affecting absorption include the formulation used and the presence of food, which may slightly delay absorption but does not significantly impact overall bioavailability.

Distribution:
Ketorolac distributes extensively throughout body tissues and fluids, with a volume of distribution ranging between 0.1–0.2 L/kg. It is highly bound to plasma proteins, predominantly albumin, with binding rates exceeding 99%, which limits free drug concentration but prolongs the duration of action. The distribution favors inflamed tissues, which is beneficial for its anti-inflammatory and analgesic effects. Ketorolac crosses the placenta and is detected in breast milk, warranting precautions during pregnancy and lactation. It poorly penetrates the central nervous system but achieves effective concentrations at peripheral nociceptive sites.

Metabolism:
Ketorolac is metabolized primarily in the liver via hydroxylation and subsequent conjugation pathways. Cytochrome P450 enzymes facilitate these biotransformations, with additional contributions from phase II conjugation enzymes such as UDP-glucuronosyltransferases. The metabolic process renders ketorolac into inactive metabolites that are more water-soluble and easier to eliminate. Genetic polymorphisms affecting hepatic enzymes may influence the metabolism rate, potentially altering plasma drug levels and efficacy. No active metabolites have been identified, minimizing concerns about cumulative pharmacologic effects.

Elimination:
Ketorolac and its metabolites are largely eliminated via renal excretion, accounting for approximately 92% of the administered dose. The elimination half-life ranges from 4 to 6 hours in healthy adults but may be prolonged in patients with impaired renal function. The drug undergoes glomerular filtration as well as tubular secretion, and dosing adjustments are necessary in patients with renal insufficiency to avoid toxicity. A minor route of elimination is biliary excretion. Ketorolac is generally not removed significantly by hemodialysis or peritoneal dialysis. Clinical implications of its elimination profile include the restriction of use to five days or less to minimize renal adverse effects and accumulation risks.

Dosage Forms

Available Dosage Forms:
- Oral tablets: 10 mg strength
- Intramuscular (IM) injection: 15 mg/mL and 30 mg/mL vials
- Intravenous (IV) injection: 15 mg/mL and 30 mg/mL vials
- Nasal spray (brand name Sprix): typically 15.75 mg per spray

Dosages for Adults and Adolescents:
- Oral: Typically prescribed at 10 mg every 4 to 6 hours as needed for pain, not to exceed 40 mg per day. Treatment duration is limited to 5 days or less.
- IM or IV Injection: Initial dose of 15-30 mg administered every 6 hours as needed, with a maximum daily dosage of 120 mg (usually 60 mg for patients over 65 or with renal impairment). Total combined duration of parenteral and oral therapy should not exceed 5 days.
- Nasal Spray: Administered as one spray (15.75 mg) into each nostril every 6 to 8 hours, not to exceed 4 sprays in 24 hours (i.e., 125 mg). Duration of use not exceeding 5 days.

Specific Patient Populations:
- Renal Impairment: Dosage adjustments are critical. IM/IV dose reduced to 15 mg every 6 hours or less. Oral and nasal doses must be adjusted or avoided if renal function is significantly compromised.
- Elderly: Increased sensitivity to ketorolac adverse effects; dosing usually reduced to 15 mg every 6 hours parenterally.
- Pediatric Use: Safety and efficacy not established in children under 2 years; generally not recommended.
- Pregnancy and Lactation: Contraindicated in the third trimester due to risks of fetal cardiovascular and renal effects; use during breastfeeding is generally discouraged.

Clinical guidelines emphasize strict limitation of ketorolac use to a maximum of five days due to concerns of nephrotoxicity, gastrointestinal bleeding, and other serious adverse events with prolonged therapy.

Mechanism Of Action

Ketorolac belongs to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) and mediates its effects primarily through the inhibition of cyclooxygenase (COX) enzymes, specifically COX-1 and COX-2. These enzymes catalyze the conversion of arachidonic acid to prostaglandins, key mediators of inflammation, pain, and fever. By competitively blocking COX active sites, ketorolac effectively reduces prostaglandin synthesis, leading to decreased sensitization of peripheral nociceptors and attenuation of inflammatory processes.

At the molecular level, ketorolac exhibits a reversible, non-selective inhibition of both COX isoforms, which accounts for its potent analgesic and anti-inflammatory properties. The inhibition of COX-1 also reduces the production of protective prostaglandins in the gastric mucosa and renal vasculature, contributing to some of the drug's adverse effects such as gastrointestinal toxicity and renal impairment. The analgesic action is particularly valuable for moderate to severe pain, including postoperative pain, by reducing peripheral sensitization and nociceptive signaling.

Cellular pathways affected by ketorolac include reduction of prostaglandin E2 (PGE2) production, a potent mediator involved in pain perception and inflammation. Lowering PGE2 levels leads to decreased vascular permeability, reduced edema formation, and diminished pain signals transmitted to the central nervous system. Additionally, ketorolac may modulate platelet aggregation due to COX-1 inhibition, thereby exerting mild antiplatelet effects.

Clinically, ketorolac's mechanism translates into rapid onset of pain relief without opioid-related sedative or addictive effects, making it a valuable agent in multimodal analgesia. Its efficacy is comparable to some opioids for short-term use, but the lack of central nervous system depression means it does not produce euphoria or respiratory depression. Comparative studies have shown ketorolac offers significant analgesia with a different safety profile than narcotics. Ongoing research into COX-2 selective inhibitors aims to retain analgesic effects while minimizing gastrointestinal and renal toxicity, but ketorolac remains widely used due to its potent action and parenteral availability for acute pain settings.

Pharmacological Actions

Inhibition of cyclooxygenase enzymes COX-1 and COX-2 reducing prostaglandin synthesis.
Potent analgesic effect for moderate to severe pain management.
Anti-inflammatory action through reduction of inflammatory prostaglandins.
Antipyretic activity by lowering prostaglandin-mediated hypothalamic temperature regulation.
Mild antiplatelet effect due to COX-1 inhibition affecting thromboxane A2 production.
Reduction in peripheral sensitization of nociceptors, diminishing pain signaling.
Decreased vascular permeability leading to reduced edema formation.
Rapid onset of action when administered parenterally, suitable for acute pain control.
Temporary renal prostaglandin inhibition impacting renal blood flow.
No central opioid receptor activity, hence no narcotic side effects.
Reversible enzyme inhibition allowing restoration of physiological prostaglandin levels post-treatment.
Effective in postoperative pain management as part of multimodal analgesic regimens.
Crosses placenta and into breastmilk, necessitating precautions in pregnancy and lactation.
Interaction potential with other drugs metabolized by liver enzymes.

Therapeutic Or Clinical Uses

Short-term management of moderate to severe acute pain, typically post-surgical.
Management of renal colic pain and musculoskeletal injuries requiring potent analgesia.
Alternative to opioid analgesics in postoperative settings to reduce opioid consumption.
Treatment of moderate to severe pain in patients where opioid use is contraindicated.
Use in combination with other analgesics as part of a multimodal pain management strategy.
Control of inflammation and pain associated with soft tissue injuries.
Management of painful inflammatory conditions requiring short-duration NSAID therapy.
Used in hospital settings for parenteral pain control, especially intravenous or intramuscular routes.
Nasal spray formulation for non-invasive pain control in ambulatory care.
Used when oral administration is not feasible due to patient condition or surgical status.
Pain relief in cases where rapid analgesic effect is required.
Short-term treatment duration limits potential for gastrointestinal and renal adverse effects.
Adjunctive therapy in managing postoperative orthopedic and dental pain.
Role in palliative care for specific pain conditions requiring NSAID analgesics.
Treatment not recommended beyond five days due to safety concerns.

Side Or Adverse Effects

Gastrointestinal irritation including nausea, dyspepsia, abdominal pain, and diarrhea.
Risk of serious gastrointestinal bleeding, ulceration, or perforation, especially with prolonged use.
Elevated risk of cardiovascular events such as heart attack and stroke with long-term or high-dose use.
Renal impairment or failure, particularly in patients with pre-existing kidney disease or dehydration.
Allergic reactions ranging from mild urticaria to severe anaphylaxis.
Headache, dizziness, and drowsiness reported in some patients.
Fluid retention and edema leading to weight gain and peripheral swelling.
Hepatic adverse effects including elevated liver enzymes, jaundice, and rarely liver injury.
Hematologic effects such as anemia and increased bleeding risk.
Potential exacerbation of asthma symptoms in sensitive individuals.
Injection site reactions including pain or irritation with IM administration.
Rare severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
Central nervous system side effects including confusion or nervousness in vulnerable patients.
Risk of interference with platelet function leading to prolonged bleeding times.
Possibility of impaired wound healing due to anti-inflammatory effects.

Precautions

Use only for short-term treatment not exceeding five days to minimize risk of adverse effects.
Screen patients for history of gastrointestinal ulcers or bleeding before prescribing.
Assess renal function prior to therapy and monitor during treatment, especially in elderly or dehydrated patients.
Avoid use in patients with known hypersensitivity to ketorolac, aspirin, or other NSAIDs.
Cautiously administer in patients with cardiovascular disease or risk factors for stroke.
Monitor for signs of bleeding or anemia during therapy, particularly in high-risk populations.
Avoid concomitant use with other NSAIDs or aspirin to prevent additive toxicity.
Advise patients to avoid alcohol consumption to reduce gastrointestinal bleeding risk.
Use caution in patients on anticoagulants, antiplatelet agents, or selective serotonin reuptake inhibitors (SSRIs).
Discontinue use prior to surgical procedures to reduce bleeding complications.
Pregnancy: contraindicated in the third trimester due to risk of fetal harm.
Avoid use in breastfeeding without consulting healthcare provider due to excretion in breast milk.
Patients with asthma or history of NSAID-induced bronchospasm require careful monitoring.
Adjust dosage or avoid use in hepatic impairment due to altered metabolism.
Educate patients on recognizing signs of serious adverse effects such as chest pain or severe rash.

Warnings

Risk of fatal gastrointestinal bleeding, ulceration, and perforation, which may occur without warning.
Increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke.
Contraindicated in patients with active or recent bleeding, including intracranial hemorrhage.
Not to be used in patients with severe renal impairment or volume depletion.
Avoid use in late pregnancy (third trimester) due to risk of premature closure of fetal ductus arteriosus.
Use during breastfeeding is generally discouraged due to potential effects on the infant.
Potential for severe hypersensitivity reactions including anaphylaxis and angioedema.
Do not co-administer with other NSAIDs or pentoxifylline due to increased bleeding risk.
Avoid in patients scheduled for surgery, especially coronary artery bypass graft (CABG) procedures.
Concomitant use with anticoagulants or thrombolytics increases bleeding risk.
May impair renal function leading to acute renal failure, particularly in vulnerable populations.
Use with caution in elderly patients who may have increased sensitivity to adverse effects.
Alcohol consumption can potentiate gastrointestinal toxicity.
Discontinue immediately if signs of serious skin rash, liver dysfunction, or bleeding develop.
Use lowest effective dose for the shortest possible duration to minimize risks.

Contraindication

Active or recent gastrointestinal bleeding or ulceration.
Known hypersensitivity to ketorolac, aspirin, or other NSAIDs.
History of severe allergic reaction or asthma exacerbation associated with NSAIDs.
Patients with bleeding or blood-clotting disorders.
Significant renal impairment or dehydration.
Use in late pregnancy, particularly third trimester.
Patients scheduled for surgery, especially coronary artery bypass graft (CABG).
Concurrent use of other NSAIDs, aspirin, or pentoxifylline.
Severe hepatic impairment.
History of intracranial bleeding or closed head injury.
Breastfeeding when safer alternatives are available.
Known history of severe skin reactions to NSAIDs.
Patients with active or recent bleeding within the nervous system.
Use beyond five days of therapy.
Patients who are allergic to any component of the formulation.

Drug Interactions

Concomitant use with other NSAIDs increases risk of gastrointestinal and renal toxicity.
Interaction with anticoagulants (warfarin, heparin) heightens bleeding risk.
Combination with corticosteroids increases gastrointestinal side effects.
May increase lithium levels leading to lithium toxicity.
Methotrexate clearance may be reduced, increasing toxicity risk when used concurrently.
Potentiation of antihypertensive drug effects may be diminished; monitor blood pressure closely.
Interaction with selective serotonin reuptake inhibitors (SSRIs) may raise bleeding tendency.
Seizure medications such as carbamazepine or phenytoin may alter ketorolac metabolism.
Interaction with diuretics and ACE inhibitors can exacerbate renal impairment.
Probenecid may reduce renal clearance of ketorolac, increasing plasma levels.
Pentoxifylline concomitant use increases risk of bleeding complications.
Concurrent use of antiplatelet drugs leads to enhanced bleeding risk.
Alcohol potentiates gastrointestinal hemorrhage potential.
Drugs affecting cytochrome P450 enzymes may alter ketorolac metabolism and efficacy.
Careful monitoring is required when combining with immunosuppressants or antipsychotics.

Preparations Of The Drug

Oral tablets containing 10 mg of ketorolac tromethamine for short-term oral therapy.
Intramuscular injection vials with concentrations of 15 mg/mL and 30 mg/mL for slow muscle injection.
Intravenous injection formulations available as 15 mg/mL and 30 mg/mL solutions for infusion or slow IV push.
Nasal spray formulation (Sprix) delivering 15.75 mg ketorolac per spray for intranasal administration.
Generic ketorolac tromethamine products available as alternatives to branded Toradol.
Sterile single-dose vials for parenteral use to ensure dosing accuracy and sterility.
Packaging designed for hospital, outpatient, and ambulatory care settings.
Formulations free of preservatives for IV/IM administration to reduce hypersensitivity risk.
Parenteral products intended for administration by healthcare professionals only.
Oral tablets formulated to optimize absorption and patient compliance.
Available as prescription-only medications reflecting strict usage guidelines.
Nasal formulation designed for non-invasive analgesia in patients unable to tolerate oral or injectable routes.
Various packaging sizes to accommodate different clinical settings and patient needs.
Product labeling includes detailed dosing instructions and warnings to ensure safe use.
Manufactured under strict quality control to ensure potency, purity, and safety.